Basic Research on HIV Persistence (R01) | Apply Online

Opportunity Summary:

The NIH funding opportunity PAR-14-247, titled "Basic Research on HIV Persistence (R01)," supported hypothesis-driven basic research focused on why HIV-1 can persist in people even when they are receiving highly active antiretroviral therapy (HAART). The central goal was to deepen scientific understanding of the mechanisms that allow HIV to remain in the body despite effective treatment, with particular attention to the residual virus and the biological reservoirs that maintain infection over time. While the projects were basic in nature, the FOA was clearly oriented toward discoveries that could later guide the design of therapeutic strategies aimed at long-term remission without ongoing treatment (often described as a functional cure) or, ultimately, complete eradication of the remaining virus leading to a sterilizing cure.

A major emphasis of the announcement was encouraging new ideas and fresh approaches to studying HIV persistence, including the creation or improvement of experimental models and measurement tools. This included model development (for example, systems that better reproduce latent or persistent infection) and assay development (methods to detect, quantify, and characterize persistent virus and infected cells). The intent was to strengthen the foundational science and the research toolkit needed for the next generation of cure-oriented studies, recognizing that progress toward remission or eradication depends heavily on having reliable ways to model persistence and accurately measure very low levels of virus and reservoir activity.

Mechanistically, the FOA targeted the basic biology underlying persistent infection in the setting of suppressive therapy, which often involves complex interactions among viral latency, cellular reservoirs, tissue microenvironments, and host immune responses. Projects responsive to this type of initiative typically explore questions such as how HIV establishes and maintains long-lived reservoirs, what cellular or anatomical sites contribute to persistence, how viral transcription and latency are regulated, what host pathways support survival of infected cells, and how immune system dynamics or inflammation may influence reservoir stability. Even though the FOA text does not list specific required topics in the excerpt provided, the framing makes it clear that the priority was rigorous, testable hypotheses that can move the field toward understanding the root causes of persistence rather than incremental or purely descriptive work.

The funding mechanism was the NIH Research Project Grant (R01), which is designed to support a discrete, specified, and circumscribed research project led by the named investigator(s). In practice, this means applicants were expected to propose a coherent set of aims, strong preliminary rationale, and a feasible plan that matches the expertise of the research team. The R01 mechanism also typically allows enough flexibility and time for in-depth basic research, including iterative optimization of models and assays, which aligns with the FOA emphasis on developing new approaches.

Administratively, this was a discretionary grant opportunity from the National Institutes of Health. The FOA anticipated around 8 awards, with an estimated total funding level of $3.5 million across all awards. No cost sharing or matching was required, which is typical for many NIH investigator-initiated research grants and lowers barriers for applicants who may not have access to non-federal matching funds.

Eligibility was broad and included many organizational types: small businesses; for-profit organizations (including those other than small businesses); nonprofit organizations (with or without 501(c)(3) status); public and private institutions of higher education; state, county, city, township, and special district governments; independent school districts; public housing authorities/Indian housing authorities; Native American tribal governments and tribal organizations; and others as further described in the announcement. The FOA also explicitly recognized a wide set of additional eligible applicants, including minority-serving institutions (such as HBCUs, Hispanic-serving institutions, AANAPISIs, Alaska Native and Native Hawaiian-serving institutions, and tribally controlled colleges and universities), faith-based or community-based organizations, eligible federal agencies, U.S. territories or possessions, regional organizations, and non-U.S. entities (foreign organizations). This breadth suggests NIH sought to encourage participation from diverse research environments and to leverage expertise wherever it exists, including internationally.

Key dates indicate the opportunity was posted and created on June 4, 2014, with an original and final closing date of January 7, 2017, and an archive date of February 7, 2017. The CFDA program areas listed span multiple NIH-relevant domains tied to infectious disease and related research landscapes, including allergy and infectious diseases, microbiology and infectious diseases, drug abuse and addiction research programs, mental health research grants, child health and human development extramural research, and oral diseases and disorders research. That spread reflects how HIV persistence research can intersect with immunology, virology, co-morbidities, behavioral health, and other clinical and biological contexts.

For applicants and interested parties at the time, the full announcement was available through the NIH grants guide at the provided link. NIH also listed the Office of Extramural Research (OER) webmaster contacts for access or technical linking issues, which is standard for NIH FOAs and indicates that detailed requirements, review criteria, and application instructions were housed in the complete FOA text.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Education Health Income Security and Social Services

Next opportunity: The Use of Polyethylene Glycol in the Pediatric Population (R01)

Previous opportunity: Basic Research on HIV Persistence (R21)

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for PAR 14 247

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (PAR 14 247) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "PAR 14 247", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.